Clinical Trial

Use of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women

Study acronym: BP-ME
Recruiting
View on ClinicalTrials.gov →
Summary
Hypertensive disorders (HD), including preeclampsia, gestational hypertension, chronic hypertension, and chronic hypertension with superimposed preeclampsia, affect around 10-20% of pregnant women in the United States and are significantly associated with maternal mortality and morbidity, particularly in the postpartum period. The prevalence of HD is on the rise in the United States and has increased from 13% in 2017 to 16% in 2019 owing to an increase in advanced maternal age, obesity, and diabetes. There are major racial disparities in HD and subsequent maternal mortality and morbidity. HD affect more than 1 in 5 delivery hospitalizations of Black women. Black women with HD are also more likely than white women with HD to have more adverse postpartum blood pressure trajectories which leads to a higher incidence of hypertension related hospital readmissions (readmission for hypertension during the first 6-weeks postpartum: 16.9% among Black women vs. 9.5% among white women, p=0.02) and cardiovascular-related adverse events. However, most of the management recommendations have been centered around blood pressure targets during the antepartum period with significantly less attention paid to the postpartum period despite evidence showing that hypertensive disorders are the most common reason for postpartum readmissions and are associated with increased maternal mortality and morbidity and a significant cost burden.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-23; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-01-08
Trial Details
NCT Number NCT06096701
Lead Sponsor University of South Carolina
Collaborators: Prisma Health-Midlands
Conditions Hypertensive Disorder
Enrollment 540 participants
Start Date 2024-02-13
Primary Completion 2027-02 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-18